Abstract

In the search for novel therapeutic targets, RNA interference screening has become a valuable tool. High-throughput technologies are now broadly accessible but their assay development from baseline remains resource-intensive and challenging. Focusing on this assay development process, we here describe a target discovery screen using pooled shRNA libraries and next-generation sequencing (NGS) deconvolution in a cell line model of Ewing sarcoma. In a strategy designed for comparative and synthetic lethal studies, we screened for targets specific to the A673 Ewing sarcoma cell line. Methods, results and pitfalls are described for the entire multi-step screening procedure, from lentiviral shRNA delivery to bioinformatics analysis, illustrating a complete model workflow. We demonstrate that successful studies are feasible from the first assay performance and independent of specialized screening units. Furthermore, we show that a resource-saving screen depth of 100-fold average shRNA representation can suffice to generate reproducible target hits despite heterogeneity in the derived datasets. Because statistical analysis methods are debatable for such datasets, we created ProFED, an analysis package designed to facilitate descriptive data analysis and hit calling using an aim-oriented profile filtering approach. In its versatile design, this open-source online tool provides fast and easy analysis of shRNA and other count-based datasets to complement other analytical algorithms.

Highlights

  • RNA interference screens have become a central method in the field of functional genomics to identify critical cancer pathways, molecular drug targets, and their therapeutic synergies [1,2,3,4,5,6,7,8]

  • Our target discovery screen is designed to identify therapeutic targets that are specific to one of two comparative conditions a and b, such as distinct oncogene expressions, drug treatments, or other synthetic lethal settings; for the purpose of assay development here modeled by distinct cell lines

  • We describe a target discovery screen using pooled shRNA libraries and Ion Proton next-generation sequencing (NGS)-based deconvolution, in a comparative screen design that is suitable to identify tumor cell-specific targets and synthetic lethal dependencies. We demonstrate that these screens can be successful from the first assay performance and without specialized screening units, assay development of this multi-step procedure remains challenging

Read more

Summary

Introduction

RNA interference screens have become a central method in the field of functional genomics to identify critical cancer pathways, molecular drug targets, and their therapeutic synergies [1,2,3,4,5,6,7,8]. 379.html), project number 01GM0869 (UD EK JP). The ERA-Net-TRANSCAN consortium, project number 01KT1310 (EK UD), and the Euro Ewing Consortium EEC, project number EU-FP7 602856 (UD), both funded under the European Commission Seventh Framework Program FP7HEALTH (http://cordis.europa.eu/). The Medical Faculty of the Westfalische WilhelmsUniversitat Munster Innovative Medizinische Forschung at the Medical Faculty of the Westfalische WilhelmsUniversitat (https://campus.uni-muenster.de/imf/ das-imf), project number PO 2 2 16 12 (JP). The funding sources had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call